| Symbol | NAUT |
|---|---|
| Name | NAUTILUS BIOTECHNOLOGY, INC. |
| Sector | INDUSTRIALS |
| Region | North America |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Address | 2701 EASTLAKE AVENUE EAST, SEATTLE, Washington, 98102, United States |
| Telephone | +1 206 333-2001 |
| Fax | — |
| — | |
| Website | https://www.nautilus.bio |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001808805 |
| Description | With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Additional info from NASDAQ: |
AH Equity Partners Bio II, L.L.C. 🔴 sold 5.0M shares of Nautilus Biotechnology, Inc. (NAUT) at $2.35 ($11.8M) Transaction Date: Jun 02, 2026 | Filing ID: 000599
Read moreNew Form SCHEDULE 13D/A - Nautilus Biotechnology, Inc. <b>Filed:</b> 2026-06-04 <b>AccNo:</b> 0001725721-26-000002 <b>Size:</b> 37 KB
Read moreNew Form DEFA14A - Nautilus Biotechnology, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001808805-26-000024 <b>Size:</b> 381 KB
Read moreNew Form DEF 14A - Nautilus Biotechnology, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001808805-26-000023 <b>Size:</b> 1 MB
Read moreNautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
Read moreNautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
Read moreDirector Patel Sujal M 🟢 acquired 25.0K shares of Nautilus Biotechnology, Inc. (NAUT) at $2.61 Transaction Date: Mar 04, 2026 | Filing ID: 000003
Read moreMowry Anna 🟢 acquired 160.0K shares (1 derivative) of Nautilus Biotechnology, Inc. (NAUT) at $2.32 Transaction Date: Mar 02, 2026 | Filing ID: 000001
Read moreDirector Mallick Parag 🟢 acquired 280.0K shares (1 derivative) of Nautilus Biotechnology, Inc. (NAUT) at $2.32 Transaction Date: Mar 02, 2026 | Filing ID: 000001
Read more